Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/F...
参考资料: 1.Beitsch PD, Whitworth PW, Hughes K, et al: Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453-460, 2019 2.Yang S, Axilbund JE, O’Leary E, et al: Underdiagnosis of hereditary breast and ovarian cancer i...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovar...
1.Beitsch PD, Whitworth PW, Hughes K, et al: Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453-460, 2019 2.Yang S, Axilbund JE, O’Leary E, et al: Underdiagnosis of hereditary breast and ovarian cancer in Medicare ...
Imaging, 3rd bullet added:For patients with germline mutations or family history of breast cancer, please refer to See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 新增:治疗后监测 Added:Post treatment monitoring ...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovar...
* Modified footnote "o" for consistency with NCCN Guidelines for Breast Cancer Risk Reduction. The footnote states "CYP2D6 genotype testing is not recommended in women who are considering tamoxifen." *为了与NCCN降低乳腺癌风险指南一致修改脚注“o”。脚注指出“在考虑他莫昔芬的女性中不建议CYP2D6基因...
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and dis...
BPI19-008: Racial Disparities in Breast Cancer Treatment Based on NCCN Quality Guidelines Background: NCCN quality measures for breast cancer include (1) radiation therapy administered within 1 year of diagnosis for women under age 70 receiving ... S Agarwal,R Rao,D Ansell - 《Journal of the...
NCCN guidelines help identify a somewhat broad group of pts requiring further genetic evaluation and a narrower one, for whom genetic testing is specifically recommended. Aims: The identification of pts requiring genetic guidance and the description of subgroups fulfilling NCCN criteria for genetic ...